With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

The medication is a dual inhibitor of the IDH mutation (IDH1 and IDH2 ... From this perspective, the discovery of a mutation in the gene encoding the protein called isocitrate dehydrogenase ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an ... targeted treatments, and gene therapies. In the relapsed/refractory (R/R) MDS market, TIBSOVO faces ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an ... targeted treatments, and gene therapies. DelveInsight has expertise in the oncology market with an ...